Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203372 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL5203905 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL5203376 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL5688777 | 0.79 | ALDH1A1 (0.40) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL5688772 | 0.79 | ALDH1A1 (0.40) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL5688778 | 0.79 | ALDH1A1 (0.40) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL5233080 | 0.75 | NOTUM (0.35) | CHRM3CHRM2CHRM1NOTUMCHRM4 | |
| SCHEMBL25340944 | 0.73 | CHRM3 (0.39) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 | |
| SCHEMBL4629180 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KEAP1NFE2L2LMNASLC6A1 | |
| SCHEMBL20595792 | 0.73 | CHRM3 (0.39) | ALDH1A1CHRM3CHRM2CHRM1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389200-A4 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-6943180-B2 | Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1389200-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002074761-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | ALDH1A1 418/4885CHRM3 2314/4885CHRM2 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.